Literature DB >> 16805080

Anticoagulation for atrial fibrillation.

Michelle Greiver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16805080      PMCID： PMC1479495     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  7 in total

1.  Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association.

Authors:  L B Goldstein; R Adams; K Becker; C D Furberg; P B Gorelick; G Hademenos; M Hill; G Howard; V J Howard; B Jacobs; S R Levine; L Mosca; R L Sacco; D G Sherman; P A Wolf; G J del Zoppo
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

2.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

Review 3.  Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.

Authors:  O Benavente; R Hart; P Koudstaal; A Laupacis; R McBride
Journal:  Cochrane Database Syst Rev       Date:  2000

4.  Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation.

Authors:  A Howitt; D Armstrong
Journal:  BMJ       Date:  1999-05-15

5.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

6.  The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics.

Authors:  S D Fihn; C M Callahan; D C Martin; M B McDonell; J G Henikoff; R H White
Journal:  Ann Intern Med       Date:  1996-06-01       Impact factor: 25.391

7.  A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study.

Authors:  Thomas J Wang; Joseph M Massaro; Daniel Levy; Ramachandran S Vasan; Philip A Wolf; Ralph B D'Agostino; Martin G Larson; William B Kannel; Emelia J Benjamin
Journal:  JAMA       Date:  2003-08-27       Impact factor: 56.272
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.